Iowa City, IA, United States of America

Karl Kohlgraf


Average Co-Inventor Count = 3.0

ph-index = 2

Forward Citations = 11(Granted Patents)


Location History:

  • Omaha, NE (US) (2010)
  • Iowa City, IA (US) (2012 - 2014)

Company Filing History:


Years Active: 2010-2014

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Karl Kohlgraf: Innovator in Cancer Treatment

Introduction

Karl Kohlgraf is a notable inventor based in Iowa City, IA (US). He has made significant contributions to the field of cancer treatment through his innovative research and patented inventions. With a total of 3 patents, Kohlgraf is dedicated to advancing medical science and improving patient outcomes.

Latest Patents

Kohlgraf's latest patents focus on compositions and methods for preventing or treating cancer. One of his key inventions relates to a MUC1 cytoplasmic tail peptide or a portion thereof. These peptides are designed to induce an immune response to MUC1-expressing tumor cells, thereby providing a potential method for preventing or treating cancer. This groundbreaking work highlights his commitment to addressing critical health challenges.

Career Highlights

Karl Kohlgraf is affiliated with the University of Nebraska, where he conducts his research and develops his innovative solutions. His work is characterized by a strong focus on cancer immunotherapy, which aims to harness the body's immune system to fight cancer more effectively.

Collaborations

Kohlgraf collaborates with esteemed colleagues, including Tom Caffrey and Michael Anthony Hollingsworth. These partnerships enhance the research efforts and contribute to the development of effective cancer treatments.

Conclusion

Karl Kohlgraf's contributions to cancer treatment through his innovative patents and collaborations underscore his role as a leading inventor in the medical field. His work continues to inspire advancements in cancer research and therapy.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…